GlassScriptPhysician profile
Amrit Lama
NPI 1649914342
$718.39
in general payments reported to CMS, 2019-2025
14 companies · $485 in 2025
The $485 reported for 2025 was more than what 78% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $28.38 · 2023: $59.27 · 2024: $146 · 2025: $485.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $690.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $690.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $141.28 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $114.75 | 2025 | Fasenra |
| Glaxosmithkline, LLC. | $110.82 | 2024 | |
| Merck Sharp & Dohme LLC | $65.34 | 2025 | Winrevair |
| Lexicon Pharmaceuticals, INC. | $55.56 | 2023-2024 | Inpefa |
| La Jolla Pharmaceutical Company | $51.83 | 2025 | Giapreza |
| Stryker Corporation | $48.88 | 2025 | Flowtriever |
| Edwards Lifesciences Corporation | $28.38 | 2022 | |
| Grifols USA, LLC | $22.81 | 2025 | Prolastin-C Liquid |
| United Therapeutics Corporation | $18.50 | 2025 | Tyvaso |
| Csl Behring | $16.52 | 2025 | Kcentra |
| Pfizer INC. | $16.01 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.09 | 2025 | |
| Abiomed | $13.62 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amrit Lama listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.